Skip to main content
Erschienen in:

08.07.2019 | Original Article – Clinical Oncology

Adjuvant carboplatin therapy in patients with clinical stage 1 testicular seminoma: is long-term morbidity increased?

verfasst von: Christian Guido Ruf, Stefan Borck, Petra Anheuser, Cord Matthies, Tim Nestler, Henrik Zecha, Hendrik Isbarn, Klaus-Peter Dieckmann

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Clinical stage (CS) 1 testicular seminoma is cured in almost 100% of cases following either retroperitoneal radiotherapy, carboplatin monotherapy, or surveillance strategies. Little is known about potential long-term effects of carboplatin. We, therefore, examined late sequelae of this drug in seminoma patients.

Patients and methods

We retrospectively identified 451 patients with CS1 testicular seminoma treated between 1994 and 2014, of whom 243 underwent carboplatin therapy [median follow-up (F/U) 96 months], 81 received radiotherapy (median F/U 142 months), and 127 underwent surveillance (median F/U 40 months). Satisfaction regarding management, as well as the following events during F/U, were analysed by questionnaire: subsequent malignant neoplasms (SMNs), cardiovascular events, arterial hypertension, peptic ulcer, tinnitus, peripheral neuropathy, hypogonadism, and infertility. The relative frequencies of the events were analysed using descriptive statistics. The frequency of observed SMNs was compared with the expected number.

Results

Patients receiving carboplatin tolerated the treatment less well (71.2%) than those under surveillance (81.9%). After carboplatin, 12 SMNs (5.0%) were noted vis-a-vis 5.0 expected. There were three cases of prostatic cancer and 3 melanomas among the SMNs. Half of these SMNs occurred early after treatment. Among the other health events, only reported hypogonadism (13.2%) appeared to be marginally increased in frequency.

Conclusions

This study found a 2.4-fold higher than expected rate of SMN—and a slightly increased rate of hypogonadism—in the long-term period following carboplatin treatment. Although further studies are needed to confirm these preliminary findings, these results are probably informative for clinicians caring for seminoma patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna MP, Nicolai N, Oldenburg J (2015) Guidelines on testicular cancer: 2015 update. Eur Urol 68:1054–1068CrossRefPubMed Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna MP, Nicolai N, Oldenburg J (2015) Guidelines on testicular cancer: 2015 update. Eur Urol 68:1054–1068CrossRefPubMed
Zurück zum Zitat Aparicio J, Maroto P, García del Muro X, Sánchez-Muñoz A, Gumà J, Margelí M, Sáenz A, Sagastibelza N, Castellano D, Arranz JA, Hervás D, Bastús R, Fernández-Aramburo A, Sastre J, Terrasa J, López-Brea M, Dorca J, Almenar D, Carles J, Hernández A, Germà JR (2014) Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG). Ann Oncol 25:2173–2178CrossRefPubMed Aparicio J, Maroto P, García del Muro X, Sánchez-Muñoz A, Gumà J, Margelí M, Sáenz A, Sagastibelza N, Castellano D, Arranz JA, Hervás D, Bastús R, Fernández-Aramburo A, Sastre J, Terrasa J, López-Brea M, Dorca J, Almenar D, Carles J, Hernández A, Germà JR (2014) Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG). Ann Oncol 25:2173–2178CrossRefPubMed
Zurück zum Zitat Bandak M, Jørgensen N, Juul A, Vogelius IR, Lauritsen J, Kier MG, Mortensen MS, Glovinski P, Daugaard G (2016) Testosterone deficiency in testicular cancer survivors—a systematic review and meta-analysis. Andrology 4(3):382–388CrossRefPubMed Bandak M, Jørgensen N, Juul A, Vogelius IR, Lauritsen J, Kier MG, Mortensen MS, Glovinski P, Daugaard G (2016) Testosterone deficiency in testicular cancer survivors—a systematic review and meta-analysis. Andrology 4(3):382–388CrossRefPubMed
Zurück zum Zitat Berghen C, Albersen M, Blanchard P, Bossi A, Briganti A, Cozzarini C, Decaestecker K, Fonteyne V, Haustermans K, Joniau S, Lim Joon D, Khoo V, Nguyen PL, Ost P, Villeirs G, Vulsteke C, Zietman A, De Meerleer G (2019) Readressing the rationale of irradiation in Stage I seminoma guidelines: a critical essay. BJU Int 124(1):35–39CrossRefPubMed Berghen C, Albersen M, Blanchard P, Bossi A, Briganti A, Cozzarini C, Decaestecker K, Fonteyne V, Haustermans K, Joniau S, Lim Joon D, Khoo V, Nguyen PL, Ost P, Villeirs G, Vulsteke C, Zietman A, De Meerleer G (2019) Readressing the rationale of irradiation in Stage I seminoma guidelines: a critical essay. BJU Int 124(1):35–39CrossRefPubMed
Zurück zum Zitat Chau C, Cathomas R, Wheater M, Klingbiel D, Fehr M, Bennett J, Markham H, Lee C, Crabb SJ, Geldart T (2015) Treatment outcome and patterns of relapse following adjuvant carboplatin for stage I testicular seminomatous germ cell tumour: Results from a 17 year UK experience. Ann Oncol 26(9):1865–1870CrossRefPubMed Chau C, Cathomas R, Wheater M, Klingbiel D, Fehr M, Bennett J, Markham H, Lee C, Crabb SJ, Geldart T (2015) Treatment outcome and patterns of relapse following adjuvant carboplatin for stage I testicular seminomatous germ cell tumour: Results from a 17 year UK experience. Ann Oncol 26(9):1865–1870CrossRefPubMed
Zurück zum Zitat Dieckmann K-P, Brüggeboes B, Pichlmeier U, Küster J, Müllerleile U, Bartels H (2000) Adjuvant treatment of clinical stage I seminoma: is a single course of carboplatin sufficient? Urology 55:102–106CrossRefPubMed Dieckmann K-P, Brüggeboes B, Pichlmeier U, Küster J, Müllerleile U, Bartels H (2000) Adjuvant treatment of clinical stage I seminoma: is a single course of carboplatin sufficient? Urology 55:102–106CrossRefPubMed
Zurück zum Zitat Dieckmann KP, Dralle-Filiz I, Heinzelbecker J, Matthies C, Bedke J, Ellinger J, Sommer J, Haben B, Souchon R, Anheuser P, Pichlmeier U (2016) Seminoma clinical stage 1—patterns of care in Germany. Urol Int 96(4):390–398CrossRefPubMed Dieckmann KP, Dralle-Filiz I, Heinzelbecker J, Matthies C, Bedke J, Ellinger J, Sommer J, Haben B, Souchon R, Anheuser P, Pichlmeier U (2016) Seminoma clinical stage 1—patterns of care in Germany. Urol Int 96(4):390–398CrossRefPubMed
Zurück zum Zitat Dieckmann KP, Richter-Simonsen H, Kulejewski M, Ikogho R, Zecha H, Anheuser P, Pichlmeier U (2018) Testicular germ-cell tumours: a descriptive analysis of clinical characteristics at first presentation. Urol Int 100(4):409–419CrossRefPubMedPubMedCentral Dieckmann KP, Richter-Simonsen H, Kulejewski M, Ikogho R, Zecha H, Anheuser P, Pichlmeier U (2018) Testicular germ-cell tumours: a descriptive analysis of clinical characteristics at first presentation. Urol Int 100(4):409–419CrossRefPubMedPubMedCentral
Zurück zum Zitat Fung C, Fossa SD, Milano MT, Oldenburg J, Travis LB (2013) Solid tumors after chemotherapy or surgery for testicular nonseminoma: a Population-Based Study. J Clin Oncol 31(30):3807–3814CrossRefPubMedPubMedCentral Fung C, Fossa SD, Milano MT, Oldenburg J, Travis LB (2013) Solid tumors after chemotherapy or surgery for testicular nonseminoma: a Population-Based Study. J Clin Oncol 31(30):3807–3814CrossRefPubMedPubMedCentral
Zurück zum Zitat Groot HJ, Lubberts S, de Wit R, Witjes JA, Kerst JM, de Jong IJ, Groenewegen G, van den Eertwegh AJM, Poortmans PM, Klümpen HJ, van den Berg HA, Smilde TJ, Vanneste BGL, Aarts MJ, Incrocci L, van den Bergh ACM, Jóźwiak K, van den Belt-Dusebout AW, Horenblas S, Gietema JA, van Leeuwen FE, Schaapveld M (2018) Risk of solid cancer after treatment of testicular germ cell cancer in the platinum era. J Clin Oncol 36(24):2504–2513CrossRefPubMed Groot HJ, Lubberts S, de Wit R, Witjes JA, Kerst JM, de Jong IJ, Groenewegen G, van den Eertwegh AJM, Poortmans PM, Klümpen HJ, van den Berg HA, Smilde TJ, Vanneste BGL, Aarts MJ, Incrocci L, van den Bergh ACM, Jóźwiak K, van den Belt-Dusebout AW, Horenblas S, Gietema JA, van Leeuwen FE, Schaapveld M (2018) Risk of solid cancer after treatment of testicular germ cell cancer in the platinum era. J Clin Oncol 36(24):2504–2513CrossRefPubMed
Zurück zum Zitat Hartmann M, Krege S, Souchon R, De Santis M, Gillessen S, Cathomas R (2011) Nachsorge von Patienten mit Hodentumoren. Interdisziplinäre evidenzbasierte Empfehlungen. [Follow-up of testicular germ cell cancer patients: Interdisciplinary evidence-based recommendations]. Urologe A 50(7):830–835CrossRefPubMed Hartmann M, Krege S, Souchon R, De Santis M, Gillessen S, Cathomas R (2011) Nachsorge von Patienten mit Hodentumoren. Interdisziplinäre evidenzbasierte Empfehlungen. [Follow-up of testicular germ cell cancer patients: Interdisciplinary evidence-based recommendations]. Urologe A 50(7):830–835CrossRefPubMed
Zurück zum Zitat Hay JH, Duncan W, Kerr GR (1984) Subsequent malignancies in patients irradiated for testicular tumours. Br J Radiol 57:597–602CrossRefPubMed Hay JH, Duncan W, Kerr GR (1984) Subsequent malignancies in patients irradiated for testicular tumours. Br J Radiol 57:597–602CrossRefPubMed
Zurück zum Zitat Horwich A, Alsanjari N, Hern RA, Nicholls J, Dearnaley DP, Fisher C (1992) Surveillance following orchidectomy for stage I testicular seminoma. Br J Cancer 65:775–778CrossRefPubMedPubMedCentral Horwich A, Alsanjari N, Hern RA, Nicholls J, Dearnaley DP, Fisher C (1992) Surveillance following orchidectomy for stage I testicular seminoma. Br J Cancer 65:775–778CrossRefPubMedPubMedCentral
Zurück zum Zitat Horwich A, Fossa SD, Huddart R, Dearnaley DP, Stenning S, Aresu M, Bliss JM, Hall E (2014) Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma. Br J Cancer 110:256–263CrossRefPubMed Horwich A, Fossa SD, Huddart R, Dearnaley DP, Stenning S, Aresu M, Bliss JM, Hall E (2014) Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma. Br J Cancer 110:256–263CrossRefPubMed
Zurück zum Zitat Kier MG, Hansen MK, Lauritsen J, Mortensen MS, Bandak M, Agerbaek M, Holm NV, Dalton SO, Andersen KK, Johansen C, Daugaard G (2016) Second malignant neoplasms and cause of death in patients with germ cell cancer: a Danish Nationwide Cohort Study. JAMA Oncol 2(12):1624–1627CrossRefPubMed Kier MG, Hansen MK, Lauritsen J, Mortensen MS, Bandak M, Agerbaek M, Holm NV, Dalton SO, Andersen KK, Johansen C, Daugaard G (2016) Second malignant neoplasms and cause of death in patients with germ cell cancer: a Danish Nationwide Cohort Study. JAMA Oncol 2(12):1624–1627CrossRefPubMed
Zurück zum Zitat Lewinshtein D, Gulati R, Nelson PS, Porter CR (2012) Incidence of second malignancies after external beam radiotherapy for clinical stage I testicular seminoma. BJU Int 109(5):706–712CrossRefPubMed Lewinshtein D, Gulati R, Nelson PS, Porter CR (2012) Incidence of second malignancies after external beam radiotherapy for clinical stage I testicular seminoma. BJU Int 109(5):706–712CrossRefPubMed
Zurück zum Zitat Mortensen MS, Lauritsen J, Gundgaard MG, Agerbæk M, Holm NV, Christensen IJ, von der Maase H, Daugaard G (2014) A nationwide cohort study of stage I seminoma patients followed on a surveillance program. Eur Urol 66:1172–1178CrossRefPubMed Mortensen MS, Lauritsen J, Gundgaard MG, Agerbæk M, Holm NV, Christensen IJ, von der Maase H, Daugaard G (2014) A nationwide cohort study of stage I seminoma patients followed on a surveillance program. Eur Urol 66:1172–1178CrossRefPubMed
Zurück zum Zitat Nöst G, Lipsky H, Würnschimmel E (1998) Carboplatinmonotherapie im klinischen Stadium I des Seminoms. Eine akzeptable Alternative? Urologe A 37:629–634CrossRefPubMed Nöst G, Lipsky H, Würnschimmel E (1998) Carboplatinmonotherapie im klinischen Stadium I des Seminoms. Eine akzeptable Alternative? Urologe A 37:629–634CrossRefPubMed
Zurück zum Zitat Oldenburg J, Aparicio J, Beyer J, Cohn-Cedermark G, Cullen M, Gilligan T, De Giorgi U, De Santis M, de Wit R, Fosså SD, Germà-Lluch JR, Gillessen S, Haugnes HS, Honecker F, Horwich A, Lorch A, Ondruscaron D, Rosti G, Stephenson A, Tandstad T (2015) Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer. Ann Oncol 26:833–838CrossRefPubMed Oldenburg J, Aparicio J, Beyer J, Cohn-Cedermark G, Cullen M, Gilligan T, De Giorgi U, De Santis M, de Wit R, Fosså SD, Germà-Lluch JR, Gillessen S, Haugnes HS, Honecker F, Horwich A, Lorch A, Ondruscaron D, Rosti G, Stephenson A, Tandstad T (2015) Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer. Ann Oncol 26:833–838CrossRefPubMed
Zurück zum Zitat Oliver RT, Mason MD, Mead GM, von der Maase H, Rustin GJ, Joffe JK, de Wit R, Aass N, Graham JD, Coleman R, Kirk SJ, Stenning SP, Collaborators MTcatE (2005) Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 366:293–300CrossRefPubMed Oliver RT, Mason MD, Mead GM, von der Maase H, Rustin GJ, Joffe JK, de Wit R, Aass N, Graham JD, Coleman R, Kirk SJ, Stenning SP, Collaborators MTcatE (2005) Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 366:293–300CrossRefPubMed
Zurück zum Zitat Oliver RT, Mead GM, Rustin GJ, Joffe JK, Aass N, Coleman R, Gabe R, Pollock P, Stenning SP (2011) Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol 29(8):957–962CrossRefPubMed Oliver RT, Mead GM, Rustin GJ, Joffe JK, Aass N, Coleman R, Gabe R, Pollock P, Stenning SP (2011) Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol 29(8):957–962CrossRefPubMed
Zurück zum Zitat Patel HD, Srivastava A, Alam R, Joice GA, Schwen ZR, Semerjian A, Allaf ME, Pierorazio PM (2017) Radiotherapy for stage I and II testicular seminomas: secondary malignancies and survival. Urol Oncol 35:606.e1–606.e7CrossRef Patel HD, Srivastava A, Alam R, Joice GA, Schwen ZR, Semerjian A, Allaf ME, Pierorazio PM (2017) Radiotherapy for stage I and II testicular seminomas: secondary malignancies and survival. Urol Oncol 35:606.e1–606.e7CrossRef
Zurück zum Zitat Powles T, Robinson D, Shamash J, Moller H, Tranter N, Oliver T (2008) The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann Oncol 19:443–447CrossRefPubMed Powles T, Robinson D, Shamash J, Moller H, Tranter N, Oliver T (2008) The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann Oncol 19:443–447CrossRefPubMed
Zurück zum Zitat Pühse G, Secker A, Kemper S, Hertle L, Kliesch S (2011) Testosterone deficiency in testicular germ-cell cancer patients is not influenced by oncological treatment. Int J Androl 34(5 Pt 2):e351–e357CrossRefPubMed Pühse G, Secker A, Kemper S, Hertle L, Kliesch S (2011) Testosterone deficiency in testicular germ-cell cancer patients is not influenced by oncological treatment. Int J Androl 34(5 Pt 2):e351–e357CrossRefPubMed
Zurück zum Zitat Rajpert-De Meyts E, McGlynn KA, Okamoto K, Jewett MA, Bokemeyer C (2016) Testicular germ cell tumours. Lancet 387(10029):1762–1774CrossRefPubMed Rajpert-De Meyts E, McGlynn KA, Okamoto K, Jewett MA, Bokemeyer C (2016) Testicular germ cell tumours. Lancet 387(10029):1762–1774CrossRefPubMed
Zurück zum Zitat Reiter WJ, Kratzik C, Brodowicz T, Haitel A, Pokorny A, Zielinski CC, Marberger M (1998) Sperm analysis and serum follicle-stimulating hormone levels before and after adjuvant single-agent carboplatin therapy for clinical stage I seminoma. Urology 52:117–119CrossRefPubMed Reiter WJ, Kratzik C, Brodowicz T, Haitel A, Pokorny A, Zielinski CC, Marberger M (1998) Sperm analysis and serum follicle-stimulating hormone levels before and after adjuvant single-agent carboplatin therapy for clinical stage I seminoma. Urology 52:117–119CrossRefPubMed
Zurück zum Zitat Reiter WJ, Brodowicz T, Alavi S, Zielinski CC, Kozak W, Maier U, Nöst G, Lipsky H, Marberger M, Kratzik C (2001) Twelve-year experience with two courses of adjuvant single-agent carboplatin therapy for clinical stage I seminoma. J Clin Oncol 19:101–104CrossRefPubMed Reiter WJ, Brodowicz T, Alavi S, Zielinski CC, Kozak W, Maier U, Nöst G, Lipsky H, Marberger M, Kratzik C (2001) Twelve-year experience with two courses of adjuvant single-agent carboplatin therapy for clinical stage I seminoma. J Clin Oncol 19:101–104CrossRefPubMed
Zurück zum Zitat Ruf CG, Isbarn H, Wagner W, Fisch M, Matthies C, Dieckmann KP (2014) Changes in epidemiologic features of testicular germ cell cancer: age at diagnosis and relative frequency of seminoma are constantly and significantly increasing. Urol Oncol 32(1):33.e1–33.e6CrossRef Ruf CG, Isbarn H, Wagner W, Fisch M, Matthies C, Dieckmann KP (2014) Changes in epidemiologic features of testicular germ cell cancer: age at diagnosis and relative frequency of seminoma are constantly and significantly increasing. Urol Oncol 32(1):33.e1–33.e6CrossRef
Zurück zum Zitat Steiner H, Scheiber K, Berger AP, Rein P, Hobisch A, Aufderklamm J, Pilloni S, Stoehr B, Aigner F, Fritzer A, Zangerl F (2011) Retrospective multicentre study of carboplatin monotherapy for clinical stage I seminoma. BJU Int 107(7):1074–1079CrossRefPubMed Steiner H, Scheiber K, Berger AP, Rein P, Hobisch A, Aufderklamm J, Pilloni S, Stoehr B, Aigner F, Fritzer A, Zangerl F (2011) Retrospective multicentre study of carboplatin monotherapy for clinical stage I seminoma. BJU Int 107(7):1074–1079CrossRefPubMed
Zurück zum Zitat Terbuch A, Posch F, Annerer LM, Bauernhofer T, Pichler M, Szkandera J, Hutterer GC, Pummer K, Partl R, Kapp KS, Stöger H, Gerger A, Stotz M (2017) Long-term cardiovascular complications in stage I seminoma patients. Clin Transl Oncol 9(11):1400–1408CrossRef Terbuch A, Posch F, Annerer LM, Bauernhofer T, Pichler M, Szkandera J, Hutterer GC, Pummer K, Partl R, Kapp KS, Stöger H, Gerger A, Stotz M (2017) Long-term cardiovascular complications in stage I seminoma patients. Clin Transl Oncol 9(11):1400–1408CrossRef
Zurück zum Zitat Travis LB, Fossa SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, Hall P, Holowaty E, Andersen A, Pukkala E, Andersson M, Kaijser M, Gospodarowicz M, Joensuu T, Cohen RJ, Boice JDJ, Dores GM, Gilbert ES (2005) Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 97:1354–1365CrossRefPubMed Travis LB, Fossa SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, Hall P, Holowaty E, Andersen A, Pukkala E, Andersson M, Kaijser M, Gospodarowicz M, Joensuu T, Cohen RJ, Boice JDJ, Dores GM, Gilbert ES (2005) Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 97:1354–1365CrossRefPubMed
Zurück zum Zitat van den Belt-Dusebout AW, de Wit R, Gietema JA, Horenblas S, Louwman MW, Ribot JG, Hoekstra HJ, Ouwens GM, Aleman BM, van Leeuwen FE (2007) Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 25:4370–4378CrossRefPubMed van den Belt-Dusebout AW, de Wit R, Gietema JA, Horenblas S, Louwman MW, Ribot JG, Hoekstra HJ, Ouwens GM, Aleman BM, van Leeuwen FE (2007) Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 25:4370–4378CrossRefPubMed
Zurück zum Zitat Zengerling F, Müller J, Schrader AJ, Schrader M (2013) Clinical stage I seminoma: is surveillance a new therapy standard? [Article in German]. Urologe A 52(9):1265–1269CrossRefPubMed Zengerling F, Müller J, Schrader AJ, Schrader M (2013) Clinical stage I seminoma: is surveillance a new therapy standard? [Article in German]. Urologe A 52(9):1265–1269CrossRefPubMed
Metadaten
Titel
Adjuvant carboplatin therapy in patients with clinical stage 1 testicular seminoma: is long-term morbidity increased?
verfasst von
Christian Guido Ruf
Stefan Borck
Petra Anheuser
Cord Matthies
Tim Nestler
Henrik Zecha
Hendrik Isbarn
Klaus-Peter Dieckmann
Publikationsdatum
08.07.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 9/2019
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-019-02965-5

Weitere Artikel der Ausgabe 9/2019

Journal of Cancer Research and Clinical Oncology 9/2019 Zur Ausgabe

Neu im Fachgebiet Onkologie

Muskeln trainieren gegen Nervenschäden durch Chemotherapie

17.07.2024 Nebenwirkungen der Krebstherapie Nachrichten

Chemotherapien können die Nerven schädigen und damit die Lebensqualität von Betroffenen zusätzlich einschränken. Wer aber auf die richtige Art trainiert, kann das absolute Risiko für Neuropathien um bis zu 40% senken.

Die beste Jahreszeit für eine Krebsimmuntherapie

16.07.2024 Onkologische Immuntherapie Nachrichten

Die Wirksamkeit von Checkpointhemmern scheint klinisch relevanten saisonalen Schwankungen zu unterliegen. Patienten mit fortgeschrittenem nichtkleinzelligem Lungenkarzinom etwa hatten das beste Outcome, wenn die PD-1-Inhibitor-Infusionen in den Wintermonaten starteten.

Partielle Nephrektomie: Videoanalysen zur Verbesserung der chirurgischen Qualität

16.07.2024 Nephrektomie Nachrichten

Je versierter Operateurinnen und Operateure sind, desto geringer ist das Risiko für Komplikationen. Eine kleine US-Studie spricht dafür, dass das auch bei Roboter-assistierten Nephrektomien gilt – und dass sich Op.-Videos für die Beurteilung eignen.        

S3-Leitlinie Endometriumkarzinom aktualisiert

15.07.2024 Endometriumkarzinom Nachrichten

Die angepasste Version der S3-Leitlinie Endometriumkarzinom enthält unter anderem Empfehlungen zu Risikofaktoren, wie der Hormonersatztherapie, sowie darüber, wann eine vaginale Brachytherapie und wann eine Perkutanbestrahlung angebracht ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.